On June 2, 2022, the company announced a decrease in its equity buyback plan. The company increased its authority by CNY 14.4 million, thereby bringing the total authorization to CNY 1105.02 million and adjusted the upper limit of the repurchase price per share to CNY 87.70 per share.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
54.37 CNY | +0.83% | -1.70% | +10.62% |
May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
May. 13 | Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.62% | 13.28B | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- 000538 Stock
- News Yunnan Baiyao Group Co.,Ltd
- Yunnan Baiyao Group Co.,Ltd announces a Decrease in Equity Buyback.